Primary bone lymphoma - the University of Miami experience

被引:49
作者
Alencar, Alvaro
Pitcher, David [2 ]
Byrne, Gerald, Jr. [3 ]
Lossos, Izidore S. [1 ,4 ]
机构
[1] Univ Miami, Miller Sch Med, Dept Med, Div Hematol Oncol, Miami, FL 33136 USA
[2] Univ Miami, Dept Orthoped, Miami, FL 33136 USA
[3] Univ Miami, Dept Pathol, Miami, FL 33136 USA
[4] Univ Miami, Sylvester Comprehens Canc Ctr, Dept Mol & Cellular Pharmacol, Miami, FL 33136 USA
关键词
Bone lymphoma; combination chemo-radiation; rituximab; NON-HODGKINS-LYMPHOMA; B-CELL LYMPHOMA; LOCALIZED AGGRESSIVE LYMPHOMA; CHEMOTHERAPY PLUS RITUXIMAB; COOPERATIVE-ONCOLOGY-GROUP; COMBINED-MODALITY THERAPY; DETUDE-DES-LYMPHOMES; PROGNOSTIC-FACTORS; ELDERLY-PATIENTS; MALIGNANT-LYMPHOMA;
D O I
10.3109/10428190903308007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Primary bone lymphoma (PBL) is a rare disease. There has been paucity of studies addressing its therapy and prognosis. We retrospectively examined PBL cases seen at the University of Miami from June 2000 to August 2007 to describe our single institution experience and review the literature. Fifty-three patients were identified with a median age of 52 (18-87) and a median follow-up of 40 months (0-106). The most common histologic type was diffuse large B-cell lymphoma (83%). Forty-one patients (77%) presented with localized disease and 48 were treated at our institution. Forty-six patients underwent chemotherapy (40 patients) and/or radiation (36 patients). Forty-four patients achieved a complete response and all patients were alive at last follow-up. The progression-free survival (PFS) was 83% at 4 years. No difference in PFS was observed between patients treated with chemotherapy or combined chemotherapy plus radiation. There was a trend toward improvement in PFS (p = 0.062) of patients with DLBCL treated with rituximab plus chemotherapy. Our single institutional experience demonstrates that the outcome of patients with PBL is excellent. Although the current data support the use of combined modality treatment for localized PBL, randomized controlled trials are needed especially now, when rituximab is routinely added to chemotherapy regimens.
引用
收藏
页码:39 / 49
页数:11
相关论文
共 67 条
[1]  
BAAR J, 1994, CANCER, V73, P1194, DOI 10.1002/1097-0142(19940215)73:4<1194::AID-CNCR2820730412>3.0.CO
[2]  
2-R
[3]  
BACCI G, 1991, J CHEMOTHERAPY, V3, P189
[4]   Primary non-Hodgkin's lymphoma of the bone: Treatment and analysis of prognostic factors for stage I and stage II [J].
Barbieri, E ;
Cammelli, S ;
Mauro, F ;
Perini, F ;
Cazzola, A ;
Neri, S ;
Bunkheila, F ;
Ferrari, S ;
Brandoli, V ;
Zinzani, P ;
Mercuri, M ;
Bacci, G .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 59 (03) :760-764
[5]   Primary lymphoma of bones [J].
Bayrakci, K ;
Yildiz, Y ;
Saglik, Y ;
Altay, M ;
Ögüt, H ;
Samur, M ;
Erekul, S .
INTERNATIONAL ORTHOPAEDICS, 2001, 25 (02) :123-126
[6]   Primary bone lymphoma: Treatment results and prognostic factors with long-term follow-up of 82 patients [J].
Beal, K ;
Allen, L ;
Yahalom, J .
CANCER, 2006, 106 (12) :2652-2656
[7]   CHOP alone compared with CHOP plus radiotherapy for localized aggressive lymphoma in elderly patients:: A study by the Groupe d'Etude des Lymphomes de I'Adulte [J].
Bonnet, Christophe ;
Fillet, Georges ;
Mounier, Nicolas ;
Ganem, Gard ;
Molina, Thierry Jo ;
Thieblemont, Catherine ;
Ferme, Christophe ;
Quesnel, Bruno ;
Martin, Claude ;
Gisselbrecht, Christian ;
Tilly, Herve ;
Reyes, Felix .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (07) :787-792
[8]  
Brousse C, 2000, JOINT BONE SPINE, V67, P446
[9]  
CARBONE PP, 1971, CANCER RES, V31, P1860
[10]   Primary lymphoma of bone: an institutional experience [J].
Catlett, Joseph P. ;
Williams, Stephen A. ;
O'Connor, Shannon C. ;
Krishnan, Jayashree ;
Malkovska, Vera .
LEUKEMIA & LYMPHOMA, 2008, 49 (11) :2125-2132